Claudio Zuccolotto
Directeur/Membre du Conseil chez VOTIS Subdermal Imaging Technologies Ltd.
Profil
Claudio Zuccolotto currently works at VOTIS Subdermal Imaging Technologies Ltd., as Director.
Postes actifs de Claudio Zuccolotto
| Sociétés | Poste | Début |
|---|---|---|
VOTIS Subdermal Imaging Technologies Ltd.
 VOTIS Subdermal Imaging Technologies Ltd. Medical SpecialtiesHealth Technology VOTIS Subdermal Imaging Technologies Ltd. is an Israeli corporation that develops a suite of devices to help diabetic patients keep their feet. The company is based in Jerusalem, Israel. The Israeli company's first device, PedCheck™, screens the feet of asymptomatic patients for PAD. If PAD is found, the second device, PedScan™, stages and monitors disease progression and the impact of therapies applied by the patient's physician. The third device, PedFlo™, informs the practicing doctor regarding the level of blood flow in the foot during a revascularization procedure. All three devices use the same technology, software, and system architecture, and are safe, non-invasive, and free of ionizing radiation. The company was founded in 2017 by Andreas H. Hielscher. Merrill Weber has been the CEO of the company since 2017. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
VOTIS Subdermal Imaging Technologies Ltd.
VOTIS Subdermal Imaging Technologies Ltd. Medical SpecialtiesHealth Technology VOTIS Subdermal Imaging Technologies Ltd. is an Israeli corporation that develops a suite of devices to help diabetic patients keep their feet. The company is based in Jerusalem, Israel. The Israeli company's first device, PedCheck™, screens the feet of asymptomatic patients for PAD. If PAD is found, the second device, PedScan™, stages and monitors disease progression and the impact of therapies applied by the patient's physician. The third device, PedFlo™, informs the practicing doctor regarding the level of blood flow in the foot during a revascularization procedure. All three devices use the same technology, software, and system architecture, and are safe, non-invasive, and free of ionizing radiation. The company was founded in 2017 by Andreas H. Hielscher. Merrill Weber has been the CEO of the company since 2017. | Health Technology |
